Check-Cap Ltd. (NASDAQ:CHEK) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Friday, August 4th.
Several other equities research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Check-Cap from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Maxim Group restated a “buy” rating on shares of Check-Cap in a research note on Tuesday, May 30th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $5.00.
Shares of Check-Cap (NASDAQ:CHEK) traded up 8.38% during mid-day trading on Friday, reaching $1.81. 54,402 shares of the company traded hands. The stock’s 50 day moving average is $1.85 and its 200 day moving average is $2.05. Check-Cap has a 52-week low of $1.65 and a 52-week high of $2.95. The stock’s market capitalization is $28.29 million.
Check-Cap (NASDAQ:CHEK) last issued its earnings results on Thursday, August 10th. The medical research company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. On average, analysts anticipate that Check-Cap will post ($0.61) earnings per share for the current year.
An institutional investor recently raised its position in Check-Cap stock. Knott David M increased its stake in Check-Cap Ltd. (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned approximately 1.05% of Check-Cap worth $349,000 as of its most recent filing with the SEC. 13.35% of the stock is currently owned by hedge funds and other institutional investors.
Check-Cap Company Profile
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
